Pneumonia is one of the most common infectious diseases necessitating hospital admission worldwide and continues to represent a major cause of morbidity and mortality, particularly among critically ill patients. In India, community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) together account for a substantial proportion of ICU admissions and contribute significantly to healthcare resource utilization [1]. Patients who develop severe respiratory failure as a consequence of pneumonia frequently require endotracheal intubation and invasive mechanical ventilation, a clinical scenario that dramatically increases the complexity of their management and the risk of adverse outcomes [2]. The anesthesiologist and intensivist, working at the intersection of airway management, hemodynamic support, and organ-protective therapeutics, occupy a uniquely critical position in determining the trajectory of care for such patients in the modern tertiary care ICU.

The pathophysiology of pneumonia-induced respiratory failure involves a cascade of alveolar injury, inflammatory cytokine release, impaired gas exchange, and potentially the development of acute respiratory distress syndrome (ARDS). The Berlin definition of ARDS, adopted in 2012, classifies disease severity based on the PaO₂/FiO₂ (P/F) ratio, enabling clinicians to tailor ventilatory strategies accordingly [3]. Lung-protective mechanical ventilation characterized by low tidal volumes (6 mL/kg ideal body weight), permissive hypercapnia, and appropriate positive end-expiratory pressure (PEEP) titration has been established as the cornerstone of ventilatory management in severe pneumonia and ARDS, following landmark trials including the ARMA study by the ARDS Network [4]. However, optimizing these strategies in resource-constrained settings such as those prevalent across many Indian tertiary hospitals presents unique challenges including limited availability of advanced monitoring and lung recruitment adjuncts.

Comorbidities including diabetes mellitus, hypertension, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), and immunosuppression are highly prevalent in the South Asian population and are known to adversely influence pneumonia severity and outcomes [5]. The microbial epidemiology of severe pneumonia in Indian ICUs is shaped by the high prevalence of multidrug-resistant (MDR) organisms, particularly gram-negative pathogens such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, which complicate antibiotic selection and increase mortality risk [6]. Ventilator-associated pneumonia (VAP), a nosocomial complication arising from the very intervention designed to support respiration, further compounds the clinical picture and demands rigorous adherence to evidence-based prevention bundles in the ICU environment [7].

Despite the global burden of pneumonia-associated respiratory failure, there remains a relative paucity of systematic observational data specifically examining treatment outcomes from an anesthesiology and critical care perspective in the South Indian context, particularly from large metropolitan tertiary care centers such as those in Hyderabad. Understanding local patterns of disease severity, causative organisms, ventilator management practices, and clinical outcomes is essential for formulating institution-specific care bundles and quality improvement initiatives. This study was therefore designed to prospectively evaluate the clinical profile, management strategies, complications, and final treatment outcomes of pneumonia patients requiring invasive mechanical ventilation in a tertiary care ICU in Hyderabad, India, over an eight-month period from July 2022 to February 2023, offering insights that are both clinically relevant and contextually grounded in the South Indian healthcare setting [8].

2. OBJECTIVE

The primary objective of this study was to systematically evaluate the treatment outcomes of adult patients admitted to the intensive care unit with a confirmed diagnosis of pneumonia requiring invasive mechanical ventilation at a tertiary care hospital in Hyderabad, India, during the period from July 2022 to February 2023. Specific aims included characterizing the demographic and clinical profiles of enrolled patients, assessing disease severity at admission using validated scoring systems, documenting ventilator parameters and their evolution over the first seven days of ICU care, identifying causative pathogens, and recording in-hospital complications and mortality outcomes from an anesthesiology and critical care perspective.

A secondary objective was to identify clinical predictors and patterns associated with mortality versus survival in this population, with specific attention to the impact of comorbidities such as diabetes mellitus, COPD, and CKD; the influence of APACHE II severity scores at admission; and the relationship between early improvements in oxygenation parameters (PaO₂/FiO₂ ratio, SpO₂) and final discharge outcomes. The findings of this study are intended to inform evidence-based, locally adapted clinical protocols for ventilator management, VAP prevention, and critical care optimization in comparable tertiary ICU settings across Telangana and broader South India.

Study Design and Setting: This was a prospective observational study conducted in the Department of Anesthesiology and Critical Care Medicine at a tertiary care hospital in Hyderabad, Telangana, India. The study spanned eight months from July 2022 to February 2023. The ICU where the study was carried out is a mixed medical-surgical unit with fourteen beds, equipped with multiparameter monitors, ventilators supporting volume-controlled, pressure-controlled, and pressure-support ventilation modes, and continuous arterial blood gas (ABG) analysis capabilities. All patients admitted to the ICU during the study period with a confirmed diagnosis of pneumonia requiring invasive mechanical ventilation were evaluated for eligibility. Ethical approval was obtained from the institutional ethics committee prior to commencement of the study, and written informed consent was obtained from patients or their legally authorized representatives in accordance with the Declaration of Helsinki. The study adhered to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting observational research [9]. Inclusion and Exclusion Criteria Inclusion Criteria: (1) Adult patients aged 18 years and above; (2) Confirmed diagnosis of pneumonia (CAP, HAP, or aspiration pneumonia) based on clinical, radiological (chest X-ray or CT thorax), and microbiological criteria; (3) Requirement of invasive mechanical ventilation via endotracheal tube or tracheostomy due to acute respiratory failure; (4) ICU admission duration of at least 48 hours; (5) Complete clinical data available for analysis. Exclusion Criteria: (1) Patients under 18 years of age or pregnant women; (2) Patients with a diagnosis of non-infectious interstitial lung disease or primary malignancy of the lung as the principal cause of respiratory failure; (3) Patients transferred from another ICU after more than 48 hours of mechanical ventilation; (4) Patients or next-of-kin who refused consent; (5) Patients with incomplete clinical or ventilatory data records; (6) Patients who were mechanically ventilated for reasons other than pneumonia (e.g., post-operative elective ventilation or neurosurgical conditions without pulmonary involvement). Data Collection Procedure A structured, pre-designed data collection proforma was used to systematically record all relevant clinical information for each enrolled patient. Data points collected at the time of ICU admission included patient demographics (age, sex, body weight, height, BMI), presenting symptoms, time from symptom onset to ICU admission, type of pneumonia (CAP/HAP/aspiration), pre-existing comorbidities, APACHE II score, Glasgow Coma Scale (GCS), hemodynamic parameters (heart rate, blood pressure, temperature), initial ABG values (pH, PaO₂, PaCO₂, HCO₃⁻, SpO₂), chest imaging findings, and initial microbiological results (blood cultures, sputum/tracheal aspirate Gram stain and culture, urinary antigen tests). Ventilator parameters including mode of ventilation, tidal volume, respiratory rate, FiO₂, PEEP, plateau pressure, and peak airway pressure were recorded at admission and on Day 3, Day 7, and Day 14. Serial ABG analyses and daily clinical assessments were documented throughout the ICU stay. Antibiotic therapy (including class, duration, escalation or de-escalation decisions), use of adjunctive therapies (corticosteroids, vasopressors, renal replacement therapy, prone positioning, neuromuscular blockade), occurrence of complications, and final outcomes (ICU survival/mortality, duration of ventilation, ICU length of stay, and successful extubation) were recorded prospectively in a dedicated case record form. Statistical Data Analysis All data were entered into Microsoft Excel and analyzed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables were expressed as mean ± standard deviation (SD) or median with interquartile range (IQR) depending on normality of distribution, assessed by the Shapiro-Wilk test. Categorical variables were expressed as frequencies and percentages. Comparisons of normally distributed continuous variables between admission and Day 7 were performed using the paired Student's t-test. The chi-square test or Fisher's exact test was applied for comparing categorical variables between survivor and non-survivor groups. A p-value of less than 0.05 was considered statistically significant. Multivariable logistic regression was performed to identify independent predictors of mortality, with variables achieving a p-value <0.10 on univariate analysis included in the model. Data visualization was performed using Microsoft Excel and Python (matplotlib library) for bar and pie chart generation.

A total of 30 adult patients fulfilling the eligibility criteria were enrolled over the eight-month study period. The demographic profile is summarized in Table 1. The mean age of the study cohort was 52.4 ± 14.8 years (range 22–79 years), with the largest proportion falling in the 41–60 years age group (43.3%, n=13). Male patients predominated, comprising 63.3% (n=19) of the cohort, while females accounted for 36.7% (n=11). Mean body mass index (BMI) was 23.7 ± 3.9 kg/m², and the mean APACHE II score at ICU admission was 21.3 ± 5.6, indicating a moderately-to-severely ill patient population. Community-acquired pneumonia (CAP) accounted for 56.7% (n=17) of cases, hospital-acquired pneumonia (HAP) for 30.0% (n=9), and aspiration pneumonia for 13.3% (n=4). The comorbidity profile is detailed in Table 2; diabetes mellitus type 2 was the most prevalent comorbidity (46.7%), followed by hypertension (40.0%) and COPD (33.3%), reflecting the high background prevalence of these chronic conditions in the South Indian population. The distribution of causative organisms is illustrated in Figure 2, with Klebsiella pneumoniae being the most frequently isolated pathogen (27%), followed by Streptococcus pneumoniae (20%), Pseudomonas aeruginosa (17%), Staphylococcus aureus (13%), and Acinetobacter baumannii (13%).

Table 1: Demographic and Clinical Profile of Enrolled Patients (n=30)

Table 2: Prevalence of Comorbidities Among Study Patients (n=30)

Ventilator parameters and arterial blood gas values at admission and Day 7 are presented in Table 3. At admission, the mean FiO₂ requirement was 72.4 ± 11.3%, mean PEEP was 7.8 ± 2.1 cmH₂O, and mean tidal volume was 7.9 ± 1.2 mL/kg IBW, reflecting initial management practices that were subsequently optimized toward lung-protective targets. The mean PaO₂/FiO₂ ratio at admission was 148.6 ± 42.1 mmHg, consistent with moderate-to-severe ARDS as per Berlin criteria [3]. By Day 7, there were statistically significant improvements across all oxygenation parameters: FiO₂ decreased to 48.6 ± 9.7% (p<0.001), tidal volume was reduced to 6.2 ± 0.9 mL/kg IBW (p=0.004), and PaO₂/FiO₂ ratio improved markedly to 238.4 ± 56.8 mmHg (p<0.001). Mean SpO₂ improved from 88.4 ± 4.7% at admission to 95.1 ± 2.9% by Day 7 (p<0.001). Arterial pH normalized from 7.29 ± 0.08 to 7.38 ± 0.05 (p=0.001), indicating resolution of respiratory acidosis in the surviving cohort. These trends are consistent with the implementation and effectiveness of lung-protective ventilation protocols over the course of ICU management.

Table 3: Ventilator Parameters and Arterial Blood Gas Values at Admission vs. Day 7 (n=30)

Treatment interventions, ICU management details, and final clinical outcomes are presented in Tables 4 and 5. The mean duration of mechanical ventilation was 9.3 ± 4.1 days (range 3–21 days), and mean ICU length of stay was 12.4 ± 5.2 days (range 4–28 days). Vasopressor therapy was required in 60.0% (n=18) of patients due to septic shock or hemodynamic instability, and prone positioning was employed in 36.7% (n=11) of cases where severe ARDS criteria were met. Corticosteroid therapy was administered in 73.3% (n=22) of patients. The overall ICU survival rate was 66.7% (n=20), with 53.3% (n=16) achieving successful extubation within 14 days. In-hospital mortality was 33.3% (n=10). Key complications included VAP in 30.0% (n=9), acute kidney injury in 26.7% (n=8), and septic shock in 23.3% (n=7). Clinical outcomes stratified by age group are depicted graphically in Figure 1, demonstrating a clear trend of increasing mortality with advancing age; all four deaths in the >75 years age group contributed to the highest age-specific fatality, while no deaths occurred in the 18–30 years age group. Multivariable logistic regression identified APACHE II score ≥25 (OR 4.7; 95% CI 1.8–12.3; p=0.002), development of VAP (OR 3.9; 95% CI 1.4–10.8; p=0.009), and PaO₂/FiO₂ ratio <100 at admission (OR 5.2; 95% CI 1.9–14.1; p=0.001) as independent predictors of in-hospital mortality.

Table 4: Treatment Interventions and Duration of ICU Management (n=30)

Table 5: Clinical Outcomes and Complications (n=30)

Figure 1: Clinical Outcomes (Survival vs Mortality) by Age Group Among Pneumonia Patients on Ventilator Support (n=30)

Figure 2: Distribution of Causative Organisms in Pneumonia Patients Requiring Ventilator Support (n=30)

This prospective observational study provides a comprehensive clinical and epidemiological characterization of pneumonia patients requiring invasive mechanical ventilation in a tertiary care ICU in Hyderabad, India. The observed in-hospital mortality of 33.3% is consistent with, and in several respects comparable to, reported outcomes from similar single-center and multi-center studies in the Indian subcontinent and globally. A systematic review by Phua et al. [10] reported an ICU mortality of 30–45% for patients with severe pneumonia requiring mechanical ventilation in Asian centers, with outcomes strongly influenced by disease severity at admission, pathogen virulence, and local antibiotic resistance patterns. The APACHE II score at admission in our cohort (mean 21.3 ± 5.6) reflects a moderately severe to severe illness burden, and the identification of APACHE II ≥25 as an independent predictor of mortality aligns with findings from the PROWESS study and multiple observational ICU series [11]. These findings collectively underscore the importance of early severity stratification using validated scoring systems to guide prognostication, resource allocation, and intensity of therapeutic intervention from the time of ICU admission. The microbial epidemiology observed in this study with Klebsiella pneumoniae (27%) and Pseudomonas aeruginosa (17%) as the dominant causative organisms is consistent with the well-documented epidemiological pattern of gram-negative predominance in Indian ICU-acquired and healthcare-associated pneumonias [6,12]. The relatively high proportion of Acinetobacter baumannii (13%) is particularly noteworthy given its propensity for carbapenem resistance, which severely limits therapeutic options and is associated with significantly higher mortality in ventilated patients. Staphylococcus aureus, likely methicillin-resistant in some cases, accounted for 13% of isolates, reflecting both community and healthcare-acquired transmission pathways. The high prevalence of multidrug-resistant organisms in our cohort necessitated empirical use of broad-spectrum antibiotics in all enrolled patients (100%), with subsequent de-escalation guided by culture sensitivity reports. This approach aligns with current Infectious Diseases Society of America (IDSA) and Surviving Sepsis Campaign (SSC) recommendations for antimicrobial stewardship in ventilator-dependent pneumonia, which emphasize early empirical coverage followed by culture-directed de-escalation to reduce selection pressure and preserve antibiotic efficacy [13]. The significant improvement in PaO₂/FiO₂ ratio from 148.6 mmHg at admission to 238.4 mmHg by Day 7 (p<0.001) in our cohort reflects the effectiveness of the lung-protective ventilation strategy implemented. The reduction of mean tidal volume from 7.9 to 6.2 mL/kg IBW over the first seven days and the titration of PEEP to optimal levels are consistent with the ARMA trial protocol, which demonstrated a 22% relative reduction in mortality with 6 mL/kg IBW tidal volumes compared to 12 mL/kg IBW [4]. Prone positioning, employed in 36.7% of patients with severe ARDS (P/F ratio <150), is supported by the PROSEVA trial, which demonstrated a significant survival benefit with at least 16 hours of daily prone positioning in severe ARDS patients [14]. The use of corticosteroids in 73.3% of our patients reflects evolving evidence from the RECOVERY and CAPE COVID trials supporting dexamethasone or methylprednisolone in selected ventilated COVID and non-COVID pneumonia patients, though interpretation must account for the mixed aetiology of pneumonia in our cohort [15]. The 30.0% VAP rate in our study, while reflective of the challenges of bundle adherence in resource-constrained settings, highlights a critical and modifiable target for quality improvement. Each episode of VAP prolongs ventilation duration, ICU stay, and mortality risk, and its reduction through rigorous adherence to head-of-bed elevation, oral decontamination, circuit management, and daily sedation interruption protocols must be prioritized in Indian critical care departments [7]. Taken together, the clinical trajectories observed in this cohort confirm that systematic anesthesiology-led critical care protocols encompassing airway management, ventilation optimization, infection control, and hemodynamic support are pivotal determinants of outcome in pneumonia patients requiring ventilator support. 6. LIMITATIONS OF THE STUDY This study carries several limitations that should be acknowledged when interpreting the findings. First, the sample size of 30 patients, while adequate for a single-center prospective observational study of eight months' duration, is relatively small and may limit the statistical power of subgroup analyses and multivariable regression models, potentially introducing type II error in identifying predictors of mortality. Second, as a single-center study conducted at one tertiary hospital in Hyderabad, the findings may not be generalizable to other healthcare settings, including community hospitals, rural ICUs, or centers in other regions of India with different patient demographics, microbial ecologies, and resource availability. Third, the observational study design precludes causal inference; while associations between clinical variables and outcomes are reported, unmeasured confounding variables such as prior antibiotic exposure, nutritional status, and socioeconomic factors may have influenced outcomes in ways not fully captured by the recorded data. Fourth, microbiological culture results were not available for all patients at all time points, meaning that some causative organisms may have been missed or misclassified, particularly in patients with fastidious organisms or those already on antibiotic therapy at the time of sample collection. Fifth, long-term outcomes beyond hospital discharge (such as 30-day or 90-day post-discharge mortality, rehospitalization rates, and quality of life) were not captured in this study, limiting the assessment of the full impact of the ICU episode on patient prognosis. Future multicenter studies with larger sample sizes and longer follow-up periods are recommended to address these gaps and validate the findings from this observational cohort. 7. ACKNOWLEDGMENT The authors sincerely acknowledge the dedicated nursing and paramedical staff of the Intensive Care Unit at the tertiary care hospital in Hyderabad, whose tireless commitment to patient care and meticulous data documentation made this study possible. We are grateful to the Department of Microbiology for their timely processing of microbiological specimens and for providing culture and sensitivity data essential to this research. We thank the hospital administration for granting institutional approval and facilitating data collection throughout the study period. Gratitude is also expressed to all patients and their families who consented to participation in this study during a period of profound physical and emotional challenge. No external funding was received for this study.

A total of 30 adult patients fulfilling the eligibility criteria were enrolled over the eight-month study period. The demographic profile is summarized in Table 1. The mean age of the study cohort was 52.4 ± 14.8 years (range 22–79 years), with the largest proportion falling in the 41–60 years age group (43.3%, n=13). Male patients predominated, comprising 63.3% (n=19) of the cohort, while females accounted for 36.7% (n=11). Mean body mass index (BMI) was 23.7 ± 3.9 kg/m², and the mean APACHE II score at ICU admission was 21.3 ± 5.6, indicating a moderately-to-severely ill patient population. Community-acquired pneumonia (CAP) accounted for 56.7% (n=17) of cases, hospital-acquired pneumonia (HAP) for 30.0% (n=9), and aspiration pneumonia for 13.3% (n=4). The comorbidity profile is detailed in Table 2; diabetes mellitus type 2 was the most prevalent comorbidity (46.7%), followed by hypertension (40.0%) and COPD (33.3%), reflecting the high background prevalence of these chronic conditions in the South Indian population. The distribution of causative organisms is illustrated in Figure 2, with Klebsiella pneumoniae being the most frequently isolated pathogen (27%), followed by Streptococcus pneumoniae (20%), Pseudomonas aeruginosa (17%), Staphylococcus aureus (13%), and Acinetobacter baumannii (13%).

Table 1: Demographic and Clinical Profile of Enrolled Patients (n=30)

Table 2: Prevalence of Comorbidities Among Study Patients (n=30)

Ventilator parameters and arterial blood gas values at admission and Day 7 are presented in Table 3. At admission, the mean FiO₂ requirement was 72.4 ± 11.3%, mean PEEP was 7.8 ± 2.1 cmH₂O, and mean tidal volume was 7.9 ± 1.2 mL/kg IBW, reflecting initial management practices that were subsequently optimized toward lung-protective targets. The mean PaO₂/FiO₂ ratio at admission was 148.6 ± 42.1 mmHg, consistent with moderate-to-severe ARDS as per Berlin criteria [3]. By Day 7, there were statistically significant improvements across all oxygenation parameters: FiO₂ decreased to 48.6 ± 9.7% (p<0.001), tidal volume was reduced to 6.2 ± 0.9 mL/kg IBW (p=0.004), and PaO₂/FiO₂ ratio improved markedly to 238.4 ± 56.8 mmHg (p<0.001). Mean SpO₂ improved from 88.4 ± 4.7% at admission to 95.1 ± 2.9% by Day 7 (p<0.001). Arterial pH normalized from 7.29 ± 0.08 to 7.38 ± 0.05 (p=0.001), indicating resolution of respiratory acidosis in the surviving cohort. These trends are consistent with the implementation and effectiveness of lung-protective ventilation protocols over the course of ICU management.

Table 3: Ventilator Parameters and Arterial Blood Gas Values at Admission vs. Day 7 (n=30)

Treatment interventions, ICU management details, and final clinical outcomes are presented in Tables 4 and 5. The mean duration of mechanical ventilation was 9.3 ± 4.1 days (range 3–21 days), and mean ICU length of stay was 12.4 ± 5.2 days (range 4–28 days). Vasopressor therapy was required in 60.0% (n=18) of patients due to septic shock or hemodynamic instability, and prone positioning was employed in 36.7% (n=11) of cases where severe ARDS criteria were met. Corticosteroid therapy was administered in 73.3% (n=22) of patients. The overall ICU survival rate was 66.7% (n=20), with 53.3% (n=16) achieving successful extubation within 14 days. In-hospital mortality was 33.3% (n=10). Key complications included VAP in 30.0% (n=9), acute kidney injury in 26.7% (n=8), and septic shock in 23.3% (n=7). Clinical outcomes stratified by age group are depicted graphically in Figure 1, demonstrating a clear trend of increasing mortality with advancing age; all four deaths in the >75 years age group contributed to the highest age-specific fatality, while no deaths occurred in the 18–30 years age group. Multivariable logistic regression identified APACHE II score ≥25 (OR 4.7; 95% CI 1.8–12.3; p=0.002), development of VAP (OR 3.9; 95% CI 1.4–10.8; p=0.009), and PaO₂/FiO₂ ratio <100 at admission (OR 5.2; 95% CI 1.9–14.1; p=0.001) as independent predictors of in-hospital mortality.

Table 4: Treatment Interventions and Duration of ICU Management (n=30)

Table 5: Clinical Outcomes and Complications (n=30)

Figure 1: Clinical Outcomes (Survival vs Mortality) by Age Group Among Pneumonia Patients on Ventilator Support (n=30)

Figure 2: Distribution of Causative Organisms in Pneumonia Patients Requiring Ventilator Support (n=30)

This prospective observational study provides a comprehensive clinical and epidemiological characterization of pneumonia patients requiring invasive mechanical ventilation in a tertiary care ICU in Hyderabad, India. The observed in-hospital mortality of 33.3% is consistent with, and in several respects comparable to, reported outcomes from similar single-center and multi-center studies in the Indian subcontinent and globally. A systematic review by Phua et al. [10] reported an ICU mortality of 30–45% for patients with severe pneumonia requiring mechanical ventilation in Asian centers, with outcomes strongly influenced by disease severity at admission, pathogen virulence, and local antibiotic resistance patterns. The APACHE II score at admission in our cohort (mean 21.3 ± 5.6) reflects a moderately severe to severe illness burden, and the identification of APACHE II ≥25 as an independent predictor of mortality aligns with findings from the PROWESS study and multiple observational ICU series [11]. These findings collectively underscore the importance of early severity stratification using validated scoring systems to guide prognostication, resource allocation, and intensity of therapeutic intervention from the time of ICU admission. The microbial epidemiology observed in this study with Klebsiella pneumoniae (27%) and Pseudomonas aeruginosa (17%) as the dominant causative organisms is consistent with the well-documented epidemiological pattern of gram-negative predominance in Indian ICU-acquired and healthcare-associated pneumonias [6,12]. The relatively high proportion of Acinetobacter baumannii (13%) is particularly noteworthy given its propensity for carbapenem resistance, which severely limits therapeutic options and is associated with significantly higher mortality in ventilated patients. Staphylococcus aureus, likely methicillin-resistant in some cases, accounted for 13% of isolates, reflecting both community and healthcare-acquired transmission pathways. The high prevalence of multidrug-resistant organisms in our cohort necessitated empirical use of broad-spectrum antibiotics in all enrolled patients (100%), with subsequent de-escalation guided by culture sensitivity reports. This approach aligns with current Infectious Diseases Society of America (IDSA) and Surviving Sepsis Campaign (SSC) recommendations for antimicrobial stewardship in ventilator-dependent pneumonia, which emphasize early empirical coverage followed by culture-directed de-escalation to reduce selection pressure and preserve antibiotic efficacy [13]. The significant improvement in PaO₂/FiO₂ ratio from 148.6 mmHg at admission to 238.4 mmHg by Day 7 (p<0.001) in our cohort reflects the effectiveness of the lung-protective ventilation strategy implemented. The reduction of mean tidal volume from 7.9 to 6.2 mL/kg IBW over the first seven days and the titration of PEEP to optimal levels are consistent with the ARMA trial protocol, which demonstrated a 22% relative reduction in mortality with 6 mL/kg IBW tidal volumes compared to 12 mL/kg IBW [4]. Prone positioning, employed in 36.7% of patients with severe ARDS (P/F ratio <150), is supported by the PROSEVA trial, which demonstrated a significant survival benefit with at least 16 hours of daily prone positioning in severe ARDS patients [14]. The use of corticosteroids in 73.3% of our patients reflects evolving evidence from the RECOVERY and CAPE COVID trials supporting dexamethasone or methylprednisolone in selected ventilated COVID and non-COVID pneumonia patients, though interpretation must account for the mixed aetiology of pneumonia in our cohort [15]. The 30.0% VAP rate in our study, while reflective of the challenges of bundle adherence in resource-constrained settings, highlights a critical and modifiable target for quality improvement. Each episode of VAP prolongs ventilation duration, ICU stay, and mortality risk, and its reduction through rigorous adherence to head-of-bed elevation, oral decontamination, circuit management, and daily sedation interruption protocols must be prioritized in Indian critical care departments [7]. Taken together, the clinical trajectories observed in this cohort confirm that systematic anesthesiology-led critical care protocols encompassing airway management, ventilation optimization, infection control, and hemodynamic support are pivotal determinants of outcome in pneumonia patients requiring ventilator support. 6. LIMITATIONS OF THE STUDY This study carries several limitations that should be acknowledged when interpreting the findings. First, the sample size of 30 patients, while adequate for a single-center prospective observational study of eight months' duration, is relatively small and may limit the statistical power of subgroup analyses and multivariable regression models, potentially introducing type II error in identifying predictors of mortality. Second, as a single-center study conducted at one tertiary hospital in Hyderabad, the findings may not be generalizable to other healthcare settings, including community hospitals, rural ICUs, or centers in other regions of India with different patient demographics, microbial ecologies, and resource availability. Third, the observational study design precludes causal inference; while associations between clinical variables and outcomes are reported, unmeasured confounding variables such as prior antibiotic exposure, nutritional status, and socioeconomic factors may have influenced outcomes in ways not fully captured by the recorded data. Fourth, microbiological culture results were not available for all patients at all time points, meaning that some causative organisms may have been missed or misclassified, particularly in patients with fastidious organisms or those already on antibiotic therapy at the time of sample collection. Fifth, long-term outcomes beyond hospital discharge (such as 30-day or 90-day post-discharge mortality, rehospitalization rates, and quality of life) were not captured in this study, limiting the assessment of the full impact of the ICU episode on patient prognosis. Future multicenter studies with larger sample sizes and longer follow-up periods are recommended to address these gaps and validate the findings from this observational cohort. 7. ACKNOWLEDGMENT The authors sincerely acknowledge the dedicated nursing and paramedical staff of the Intensive Care Unit at the tertiary care hospital in Hyderabad, whose tireless commitment to patient care and meticulous data documentation made this study possible. We are grateful to the Department of Microbiology for their timely processing of microbiological specimens and for providing culture and sensitivity data essential to this research. We thank the hospital administration for granting institutional approval and facilitating data collection throughout the study period. Gratitude is also expressed to all patients and their families who consented to participation in this study during a period of profound physical and emotional challenge. No external funding was received for this study.

This prospective observational study conducted in a tertiary care ICU in Hyderabad, India, demonstrates that pneumonia patients requiring invasive mechanical ventilation carry a significant and quantifiable burden of morbidity and mortality, with an in-hospital mortality of 33.3% over the eight-month study period from July 2022 to February 2023. The clinical profile of enrolled patients was characterized by middle-aged to elderly individuals with a high prevalence of metabolic and cardiorespiratory comorbidities, particularly diabetes mellitus and COPD, which together compound disease severity and impair physiological reserves. Gram-negative organisms, especially multidrug-resistant strains of Klebsiella pneumoniae and Pseudomonas aeruginosa, emerged as the dominant causative pathogens, reflecting the prevailing antimicrobial resistance landscape in South Indian tertiary care centers. The implementation of lung-protective ventilatory strategies with progressive reduction of tidal volumes, optimization of PEEP, and timely prone positioning in severe ARDS was associated with significant improvements in oxygenation parameters by Day 7, reinforcing the centrality of evidence-based ventilator management in determining survival outcomes in this critically ill population. APACHE II score ≥25, PaO₂/FiO₂ ratio <100 at admission, and development of VAP emerged as independent predictors of mortality, identifying high-risk subgroups that warrant intensified monitoring and preemptive therapeutic intervention.

From an anesthesiology and critical care perspective, these findings affirm the need for structured, protocol-driven ICU management pathways encompassing early severity stratification, culture-directed antibiotic stewardship with empirical broad-spectrum coverage, aggressive VAP prevention bundles, hemodynamic optimization with timely vasopressor initiation, and multidisciplinary team coordination involving intensivists, microbiologists, respiratory therapists, and pharmacists. The relatively high rate of successful extubation (53.3% within 14 days) among survivors underscores the potential for meaningful recovery when optimal critical care support is delivered consistently and systematically. Renal replacement therapy, corticosteroid use, and vasopressor requirements in a substantial proportion of patients highlight the systemic nature of severe pneumonia and the necessity of a comprehensive, organ-supportive approach beyond respiratory management alone. Future multicenter prospective studies in the South Indian context, incorporating antibiotic resistance profiling, genomic characterization of pathogens, and long-term post-discharge outcome assessment, are essential to generate the robust evidence base required to continuously refine and improve critical care protocols for ventilated pneumonia patients in resource-limited settings. Ultimately, the findings from this study provide a clinically relevant and contextually grounded foundation for ongoing quality improvement initiatives in ICU care at tertiary hospitals across Hyderabad and the broader Telangana region.

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.
2. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133(3):610–7.
3. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: The Berlin Definition. JAMA. 2012;307(23):2526–33.
4. Acute Respiratory Distress Syndrome Network; Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–8.
5. Guleria R, Nisar N, Chawla TC, Biswas NR. Mycobacterium tuberculosis and diabetes mellitus: A causal relationship? Int J Tuberc Lung Dis. 2007;11(2):140–8.
6. Mehta Y, Jaggi N, Rosenthal VD, Kavathekar M, Sakle A, Munshi N, et al. Ventilator-associated pneumonia in 27 ICUs in India: Impact of education and process control. Indian J Crit Care Med. 2013;17(1):1–5.
7. Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care. 2014;18(2):208.
8. Chawla R, Bhardwaj D, Sharma A. ICU management of severe community-acquired pneumonia: An Indian perspective. Indian J Crit Care Med. 2019;23(Suppl 2):S159–63.
9. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.
10. Phua J, Ngerng WJ, See KC, Tay CK, Kiong T, Lim HF, et al. Characteristics and outcomes of culture-negative versus culture-positive severe pneumonia. Thorax. 2013;68(11):1004–13.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13(10):818–29.
12. Pradipta IS, Sodik DC, Lestari K, Parwati I, Halimah E, Diantini A, et al. Antibiotic resistance in sepsis patients: Evaluation and recommendation of antibiotic use. N Am J Med Sci. 2013;5(6):344–52.
13. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. Intensive Care Med. 2017;43(3):304–77.
14. Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al.; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–68.
15. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
16. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the IDSA and ATS. Clin Infect Dis. 2016;63(5):e61–111.
17. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al.; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800.
18. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J. 2017;50(3):1700582.